Prebiotic formulation and its effects on gut microbiota and body composition in adults
Official title: Evaluation of the Effects of the PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition
Run by Taipei Medical University · NCT07618000 · Data updated 2026-11-12
A prebiotic supplement (PI-YSP-0111) is being tested in healthy adults to see if 8 weeks of use can favorably change gut bacteria and body composition.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Taipei Medical University Academic / other |
| Locations | 2 sites (Taipei, Taiwan and 1 other locations) |
| Status | Recruiting |
| Started | April 8, 2026 |
| Main results expected | April 7, 2027 |
| Study ends | April 7, 2027 |
| Registry record updated | June 1, 2026 |
| Trial ID | NCT07618000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18–65 with BMI 23.0–40.0 kg/m² and waist measurements meeting criteria, who are willing to maintain current lifestyle during the study.
✕Probably not a fit
Individuals with current gastrointestinal diseases, recent significant weight changes, or other specified health conditions may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study will compare high- and low-dose PI-YSP-0111 against placebo over 8 weeks in healthy adults aged 18–65. Participants will provide blood, urine, and fecal samples at baseline and after 8 weeks, with body composition and questionnaires assessed at baseline, 4 weeks, and 8 weeks. Data will be analyzed with a two-way mixed-design ANOVA to explore differences between and within groups. The trial is conducted at Taipei Medical University and Taipei Municipal WanFang Hospital in Taiwan, sponsored by Taipei Medical University with collaboration from Yung Shin Pharmaceutical Co., Ltd.
Why it matters
Potential benefit: If successful, participants may experience favorable changes in gut microbiota and liver-related health markers, along with body composition improvements.
How similar studies have gone: Prior research on prebiotic formulations has shown microbiota modulation and metabolic effects, though results vary by product and population, making this study's design exploratory for PI-YSP-0111.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy males or females aged 18 to 65 years. 2. BMI between 23.0 and 40.0 kg/m². 3. Waist circumference: ≥ 90 cm for males and ≥ 80 cm for females. 4. Participants are willing to maintain their usual dietary habits, daily routines, and physical activity levels during the study period, and have no plans to relocate. 5. Participants have fully understood the study procedures and have signed the informed consent form. Exclusion Criteria: 1. Presence of gastrointestinal diseases, such as inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, or a history of bariatric surgery. 2. Recent history of acute gastroenteritis, constipation or diarrhea; psychiatric disorders (e.g., depression or schizophrenia); cardiovascular diseases (e.g., hypertension); known allergy or hypersensitivity to the investigational product; extreme dietary habits; significant body weight change (\>4.5 kg) within the past three months; recent use of antibiotics or antifungal agents; or use of medications affecting gastrointestinal function (such as probiotics, laxatives, or nonsteroidal anti-inflammatory drugs \[NSAIDs\]). 3. Exposure to unapproved medications, alcohol abuse, or substance abuse. 4. Female-specific conditions, including significant gastrointestinal symptoms during menstruation, irregular menstrual cycles, pregnancy, planned pregnancy, or breastfeeding (participants who become pregnant during the study period will also be excluded). 5. Short-term use of corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressive agents, interferons, or immunomodulatory agents within the past one month. 6. Use of any weight-loss medications (including oral agents, injections, or traditional Chinese medicine) within the past three months. 7. Participation in any other interventional clinical study within the past one month. 8. History of cancer or current malignancy within the past two years, except for non-melanoma skin cancer. 9. Occurrence of major trauma or any surgical procedures within the past one month. 10. History of diabetic ketoacidosis.
Where it's running
-
Taipei Medical University
Taipei, Taiwan, Taiwan Recruiting -
Taipei Municipal WanFang Hospital(Managed by Taipei Medical University)
Taipei, Taiwan, Taiwan Recruiting
Study contacts
- Study coordinator: Ming Ta Yang, Professor
- Email: yangrugby@tmu.edu.tw
- Phone: +886-2-27361661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Does a single dose of XBD173 change blood sugar in healthy adults?
A single dose of XBD173 is being tested in healthy adults to see if it affects fasting and after-glucose-drink blood sugar levels compared with a placebo.
-
Nurse-guided app-based brief behavioral therapy for insomnia in older adults
Aging adults with insomnia will be asked to try a nurse-supported, smartphone app therapy for four weeks to see if it helps with sleep.
-
Low-Intensity Endurance Exercise to Help Lung Cancer-Related Fatigue
This trial tests whether light, regular endurance exercise can help reduce fatigue and improve quality of life for people with lung cancer in addition to their usual care.
-
Low-Intensity Endurance Exercise for Lung Cancer-Related Fatigue
A randomized trial tests whether light, regular endurance exercise can help reduce fatigue and improve quality of life for people with lung cancer.
-
Taiwan green propolis for MASLD and lipid/metabolic issues
This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.
-
Plasma-Activated Water for fibromyalgia symptoms
This study tests whether drinking plasma-activated water can help reduce widespread pain and related symptoms in adults with fibromyalgia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.